MyMD Pharmaceuticals, Inc. is a pharmaceutical company that focuses on developing therapeutic platforms to treat the causes of disease. They're developing MYMD-1, a drug platform that regulates the immune system to control chronic inflammation, and other cytokines, as well as treat autoimmune diseases and COVID-19-associated depression. The company is also developing Supera-CBD for treating chronic pain, addiction, and epilepsy.